Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
Novan, Inc. (Nasdaq: NOVN) announced that eight abstracts have been accepted for poster presentation at the 42nd Annual Fall Clinical Dermatology Conference in Las Vegas, NV, from October 20-23, 2022. The presentations will focus on topics such as the efficacy of berdazimer gel for molluscum contagiosum and improving psoriasis treatment adherence. Notably, berdazimer gel, a new topical agent in Phase 3 development, is positioned as a potential first-in-class treatment. Novan aims to address unmet medical needs with a robust development pipeline following the recent acquisition of EPI Health.
- Eight abstracts accepted for presentation at a key dermatology conference, indicating strong research activity.
- Berdazimer gel, a potential first-in-class treatment for molluscum contagiosum, is in Phase 3 development, which could lead to significant market advantages.
- The acquisition of EPI Health enhances Novan's commercial capabilities, promoting products for psoriasis, acne, and more.
- None.
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for poster presentation at the 42nd Annual Fall Clinical Dermatology Conference® being held October 20-23, 2022, in Las Vegas, NV.
Details for the poster presentations are as follows, which can be viewed at any time during the conference:
Title: Patient and Caregiver Experiences with Molluscum Contagiosum: Results from an Exit Interview Conducted with B-SIMPLE4 Study Participants
Authors: John C. Browning, MD, Martina Cartwright, PhD, Ira Thorla, Jr, MD, Susan A. Martin, MSPH, Oyebimpe Olayinka-Amao, PharmD, MPH, Tomoko Maeda-Chubachi, MD, PhD, MBA
Title: Efficacy and Safety of Topical Nitric Oxide-releasing Berdazimer Gel,
Authors: John C. Browning, MD, Carolyn Enloe, MPH, Martina Cartwright, PhD, Adelaide Hebert, MD, Tomoko Maeda-Chubachi, MD, PhD, MBA
Title: Improving Patient Acceptability and Adherence in Psoriasis Treatment
Authors: Alyssa Curcio, Christina Kontzias, Steven R. Feldman
Title: PAD Technology™: a novel topical formulation and drug delivery system
Authors: Nigel Crutchley, Michelle Georgiou, Morten Praestegaard, Fraser Steele
Title: PAD Technology™-based CAL/BDP cream demonstrates superior human skin flux properties compared to topical suspension/gel
Authors: Nigel Crutchley, Michelle Georgiou, Morten Praestegaard, Fraser Steele
Title: Enhanced skin deposition of betamethasone dipropionate into the skin of human volunteers from Calcipotriene/betamethasone dipropionate cream compared to topical suspension
Authors: Zoe D. Draelos, Matthew M. Draelos, Morten Praestegaard
Title: Calciprotriene (CAL) and Bethamethasone Dipropionate (BDP) Cream (CAL
Authors: George Han, Steve R. Feldman, Neal Bhatia, Morten Praestegaard
Title: Calcipotriene (CAL) and betamethasone dipropionate (BDP) cream demonstrates high efficacy and convenience in skin of color patients with plaque psoriasis.
Authors: Valerie Callender, Susan Taylor, Fran Cook-Bolden
For more information, please visit the conference website: https://fallclinical.health/fall-clinical-22-about
About Berdazimer
Berdazimer (sodium), the active ingredient in berdazimer gel,
About WYNZORA® (calcipotriene and betamethasone dipropionate) Cream
WYNZORA® Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate indicated for the topical treatment of plaque psoriasis in adults. Betamethasone dipropionate, a high-potency corticosteroid, has anti-inflammatory effects resulting in decreased expression of key TNF-α, IL-17A/F and IL-23 cytokines. Calcipotriene, a vitamin-D analog, adds to the anti-inflammatory effect of the corticosteroid by mediating psoriasis specific immune-modulating activity, stabilizes the Th2- and T-reg cell activity and inhibits epidermal hyperproliferation. WYNZORA® Cream uses PAD Technology™, which uniquely enables calcipotriene and betamethasone dipropionate to be combined in a stable, convenient-to-use aqueous formulation. WYNZORA® Cream was designed to provide one product for high efficacy, a favorable safety profile and patient satisfaction. While their pharmacologic and clinical effects are known, the exact mechanisms of actions of betamethasone dipropionate and calcipotriene, and WYNZORA® Cream, in plaque psoriasis are unknown.
WYNZORA® Cream - Important Safety Information
Tell your healthcare provider about all your medical conditions and all the medicines you take, including any corticosteroid medicines and any other products containing calcipotriene.
Do not use other products containing calcipotriene or a corticosteroid medicine without talking to your healthcare provider first.
WYNZORA® Cream may cause side effects, including:
- Too much calcium in your blood or urine and/or adrenal gland problems
- Cushing's syndrome, a condition that happens when your body is exposed to large amounts of the hormone cortisol
- High blood sugar and sugar in your urine
- Vision problems, including an increased risk of developing cataracts and glaucoma.
The most common side effects include upper respiratory infection, headache, and application site irritation. These are not all the possible side effects. Call your healthcare provider for medical advice about side effects.
This summary is not comprehensive. Visit www.wynzora.com to obtain the FDA-approved Full Prescribing Information.
About Novan
Novan, Inc. is a medical dermatology company primarily focused on researching, developing, and commercializing innovative therapeutic products for skin diseases. Our goal is to deliver safe and efficacious therapies to patients, including developing product candidates where there are unmet medical needs. We are developing SB206 (berdazimer gel,
Novan recently completed the acquisition of EPI Health. EPI Health equips the company with a robust commercial infrastructure across sales, marketing, and communications, as well as fully dedicated market access and pharmacy relation teams. Following the acquisition, the company employs approximately 100 staff, including sales personnel currently covering 42 territories, and promotes products for plaque psoriasis, rosacea, acne and dermatoses. Novan also has a pipeline of potential product candidates using our proprietary nitric oxide-based technology platform, NITRICIL™, to generate new treatments for multiple indications.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a privately held commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions.
Its innovative approach to address complex challenges more effectively is anchored in deep understanding of the skin biology combined with learnings from the pathophysiology across disease segments. Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.
For additional information please visit www.mc2therapeutics.com
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “target,” “anticipate,” “may,” “plan,” “potential,” “will,” “look forward to” and similar expressions, and are based on the Company’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements related to the potential benefits of the acquisition of EPI Health, the therapeutic value and benefits of the Company’s promoted products, the potential therapeutic value and benefits of the Company’s Nitricil™ platform technology and its product candidates, the potential market opportunity for the Company’s product candidates and promoted products, the Company’s pharmaceutical development of nitric oxide-releasing product candidates, such as berdazimer gel,
INVESTOR AND MEDIA CONTACT:
Jenene Thomas
JTC Team, LLC
833-475-8247
NOVN@jtcir.com
Sam Widdicombe
EPI Health, LLC
swiddicombe@epihealth.com
949-331-0269
Lonni Goltermann MC2 Therapeutics
log@mc2therapeutics.com
+45 2018 1111
FAQ
What presentations will Novan feature at the Fall Clinical Dermatology Conference 2022?
What is the significance of berdazimer gel for Novan?
When and where is the 42nd Annual Fall Clinical Dermatology Conference being held?
What are the implications of Novan's acquisition of EPI Health?